A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma

Study phase: II

Primary disease category: Cancer

Projected enrollment dates: April 2017 to November 2018

Official study title: A Phase 1/2 Study to Assess the Safety and Efficacy ofIntratumoral IMO-2125 in Combination with Ipilimumab orPembrolizumab in Patients with Metastatic Melanoma

ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02644967

You are here

A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma